The Role of HER2/neu Expression and Trastuzumab in Non-Small Cell Lung Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 75-82

  Hirsch, Fred R ^a   Langer, Corey J ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ADVANCED CANCER; ARTHRALGIA; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR RECOGNITION; NAUSEA; NEUTROPENIA; ONCOGENE NEU; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 1242341493     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.018     Document Type: Article

References (41)

1. Jemal A, Murray T, Samuels A, et al: Cancer Statistics 2003. CA Cancer J Clin 53:5-26, 2003
2. Stem DF, Heffernan PA, Weinberg RA: P185 a product of the neu proto-oncogene is a receptor-like protein associated with tyrosin kinase activity. Mol Cell Biol 6:1729-1740, 1986
3. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
4. Slamon DJ, Clark GM: Amplification of c-erbB-2 and aggressive human breast tumors? Science 240:1795-1798, 1988
5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
6. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 244:707-712, 1989
7. Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091, 1990
8. Liu E, Thor A, He M, et al: The Her-2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7:1027-1032, 1992
9. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
10. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
11. Allred DC, Swanson PE: Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 113:171-175, 2000
12. Jacobs TW, Gown AM, Yaziji H, et al: HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 113:251-258, 2000
13. Press MF, Pike MC, Chazin VR, et al: HER-2/neu expression in node-negative breast cancers: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
14. Jacobs TW, Gown AM, Yaziji H, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999
15. Mass RD, Sanders C, Charlene K, et al: The concordance between the clinical trials assays (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 19:75a, 2000 (abstr 291)
16. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
17. Tubbs RR, Pettay JD, Roche PC, et al: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positive do not get the message. J Clin Oncol 19:2714-2721, 2001
18. Schneider PM, Hung MC, Chiocca SM, et al: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968-4971, 1989
19. Kern JA, Schwartz DA, Nordberg JE, et al: P185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5187, 1990
20. Tateishi M, Ishida T, Mitsudomi T, et al: Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27:1372-1375, 1991
21. Paakko P, Nuorva K, Kamel D, et al: Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas. Am J Resp Cell Mol Biol 7:325-334, 1992
22. Tsai CM, Chang KT, Perng RP, et al: Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85:897-901, 1993
23. Hsieh CC, Chow KC, Fahn HJ, et al: Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 66:1159-1163; discussion 1163-1164, 1998
24. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456, 2002
25. Heinmöller P, Gross C, Beyser K, et al: HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of Herceptin. Clin Cancer Res 9:5238-5244, 2004
26. Pellefrini C, Falleni M, Marchetti A, et al: HER2/neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9:3645-3652, 2003
27. Schneider PM, Praeuer HW, Sroeltzing O, et al: Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83:473-479, 2000
28. Scheurle D, Jahanzeb M, Aronsohn RS, et al: HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved HercepTest. Anticancer Res 20:2091-2096, 2000
29. Yu D, Wang SS, Dulski KM, et al: C-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54:3260-3266, 1994
30. Kern JA, Slebos RJ, Top B, et al: C-erB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93:516-520, 1994
31. Verma S, Butts CA, Au HJ, et al: Incidence of Her-2/ neu in advanced non-small cell lung cancer and response to platinum based chemotherapy. Proc Am Soc Clin Oncol 20:347a, 2001 (abstr 1384)
32. Hirsch FR, Franklin WA, Veve R, et al: HER-2/neu expression in malignant lung tumors. Semin Oncol 29(suppl 4):51-58, 2002
33. Bunn PA Jr, Helfrich B, Soriano AF, et al: Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 7:3239-3250, 2001
34. Langer CJ, Adak S, Thor A, et al: Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and trastuzumab (T) in HER2/neu (+) advanced non-small cell lung cancer (NSCLC): Early analysis of E2598. Proc Am Soc Clin Oncol 202001315a (abstr 1257)
35. Krug LM, Miller VA, Crapanzano J, et al: Randomized phase II trial of trastuzumab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:333a, 2001 (abstr 1328)
36. Patel JD, Krug LM, Crapanzano J, et al: Clinical characteristics and outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with trastuzumab plus either weekly docetaxel of paclitaxel. Proc Am Soc Clin Oncol 21:305a, 2002 (abstr 1218)
37. Zinner R, Glisson BS, Pisters KM, et al: Cisptatin and gemcitabine combined with Herceptin in patients (pts) with HER2 overexpressing, untreated, advanced non-small-cell lung cancer (NSCLC): A phase II trial. Proc Am Soc Clin Oncol 20:328a, 2001 (abstr 1307)
38. Tran HT, Herbst RS, Glisson BS, et al: Herceptin in combination with cisplatin and gemcitabine in patients (pts) with HER2 overexpressing, untreated, advanced non-small-cell lung cancer (NSCLC): Final report of a phase II trial. Proc Am Soc Clin Oncol 21:307a, 2002 (abstr 1226)
39. Gatzemeier U, Groth G, Hirsh V, et al: A randomized phase II study of gemcitabine/cisplatin alone and with Herceptin in patients with HER-2-positive non-small cell lung cancer (NSCLC). Eur J Cancer 37(suppl 6):S50(abstr 173), 2001
40. Gatzmeier U, Groth G, Britts C, et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small cell lung cancer. Ann Oncol 15:19-27, 2004
41. DiNunno L, Shirazi W, Tacca A, et al: HER-2 analysis by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 49 consecutive cases of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:330a, 2002 (abstr 1318)